Pharming Group NV

As of June 30, 2026, Pharming Group NV carries a market capitalization of 850.05M, placing it among publicly traded companies globally. Its enterprise value stands at 810.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pharming Group NV's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Pharming Group NV has 707.78M shares outstanding.

As of June 30, 2026, Pharming Group NV trades at a trailing price-to-earnings ratio of 103.58. The price-to-sales ratio is 2.62, and the price-to-book ratio stands at 3.59.

As of June 30, 2026, Pharming Group NV trades at an EV/EBITDA multiple of 30.35 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 50.27 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Pharming Group NV trades at an EV/FCF ratio of 21.22, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 810.67M versus a market cap of 850.05M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pharming Group NV maintains a current ratio of 3.01, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 41.89, indicating elevated leverage, while an interest coverage ratio of 2.07 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Pharming Group NV posted a return on equity (ROE) of 3.64, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.87 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.03, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.76, useful for judging operating efficiency across full business cycles. The company generates approximately 2.14M in revenue per employee across its workforce of 150.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.76 indicates how many times Pharming Group NV sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pharming Group NV recorded 5.75M in income tax expense. That works out to an effective tax rate of 41.47, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 13.87M, leaving 8.12M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Pharming Group NV's stock has declined approximately 15.96% over the past 52 weeks. The 50-day moving average sits at 0.93, while the 200-day moving average is 1.20.

Over the twelve months ended June 30, 2026, Pharming Group NV generated 320.75M in revenue and converted that into 8.12M in net income, yielding earnings per share of 0.01. EBITDA reached 26.71M, while operating income came in at 10.81M.

As of June 30, 2026, Pharming Group NV holds 138.54M in cash and equivalents against 99.17M in total debt, resulting in a net debt position of -52.88M. Total book value stands at 236.76M, with working capital of 164.07M providing operational flexibility.

Pharming Group NV produced 30.66M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled 30.66M - equivalent to 0.04 per share.

Over the twelve months ended June 30, 2026, Pharming Group NV posted a gross margin of 86.53, reflecting its pricing power and cost economics. The operating margin of 3.37 and net profit margin of 2.53 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Pharming Group NV paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.42, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.07, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pharming Group NV shareholders.

Pharming Group NV's most recent stock split took place on November 23, 2016 with a 799:805 split ratio.

As of June 30, 2026, Pharming Group NV has an Altman Z-Score of 3.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.